ホーム › 肝臓がん（肝細胞がん） › ニューヨーク › New York City
New York City、NYにおける肝臓がん（肝細胞がん）の臨床試験
New York Cityとその周辺地域（約30マイル以内）の拠点で、肝臓がん（肝細胞がん）に関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of ZW251 in Participants With Advanced Solid Tumors
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
被験者募集中第1/2相
- Research Facility, New York
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
被験者募集中第1相
- Columbia University Irving Medical Center, New York
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
被験者募集中観察研究
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- 他1件
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
被験者募集中第3相
- Research Site, New York
- Research Site, New York
- Research Site, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
被験者募集中第1相
- New York Cancer & Blood Specialists, New York
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center, New York
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
被験者募集中第3相
- Mount Sinai Hospital, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
被験者募集中第1/2相
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
被験者募集中第4相
- Icahn School of Medicine at Mount Sinai, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
被験者募集中第1相
- Clinical Trial Site, New York
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
被験者募集中
- VA NY Harbor Healthcare System, New York, NY, New York
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
被験者募集中第1相
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
被験者募集中第2相
- USA04-0, New York
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
被験者募集中第1/2相
- Memorial Sloan Kettering Cancer Center - New York, New York
HOPE Against Cancer Recurrence in HCC
被験者募集中第4相
- Rutgers New Jersey Medical School (New York), New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, New York
The Dragon PLC Trial (DRAGON-PLC)
被験者募集中
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
被験者募集中第1/2相
- Memorial Sloan-Kettering Cancer Center, New York
他の都市における肝臓がん（肝細胞がん）の試験
- Houston, TX31件の研究
- Dallas, TX19件の研究
- Los Angeles, CA19件の研究
- Boston, MA18件の研究
- Cleveland, OH18件の研究
- Chicago, IL16件の研究
- Philadelphia, PA16件の研究
- Pittsburgh, PA15件の研究
- San Francisco, CA14件の研究
- Orange, CA14件の研究
- Jacksonville, FL14件の研究
- San Antonio, TX13件の研究
New York Cityにおける他の研究
- 乳がん136件の研究
- 非小細胞肺癌121件の研究
- がん（全種類）109件の研究
- 前立腺がん103件の研究
- 転移性癌93件の研究
- 大腸癌78件の研究
- 卵巣がん69件の研究
- 肺がん60件の研究
- 多発性骨髄腫60件の研究
- 膵臓がん60件の研究
- 子宮内膜がん52件の研究
- 急性骨髄性白血病51件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。